Literature DB >> 6833151

Rapid uptake by cultured tumor cells and intracellular behavior of 4'-O-tetrahydropyranyladriamycin.

S Kunimoto, K Miura, Y Takahashi, T Takeuchi, H Umezawa.   

Abstract

Intracellular levels of 4'-O-tetrahydropyranyladriamycin (THP) and adriamycin (ADM) were measured by a fluorospectroscopic method, and the former was shown to be taken up by L5178Y cells much faster than ADM; the uptake velocity of THP at 1 microgram/ml was calculated to be about 170 times faster than that of ADM. High performance liquid chromatography of cell extracts indicated that THP exists mainly in nuclei intact without hydrolysis. The effect of THP in inhibiting [3H]thymidine incorporation into DNA also indicated that THP taken up by cells rapidly went to nuclei and inhibited DNA synthesis. Fifty percent inhibition concentrations of THP or ADM on [3H]-thymidine incorporation during a 60-minute period, 15 minutes after the addition, were 0.1 microgram/ml and 4.2 micrograms/ml, respectively. Similar results were obtained when L1210 cells were used in place of the L5178Y cells.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6833151     DOI: 10.7164/antibiotics.36.312

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  23 in total

1.  (2"-R)-4'-o-tetrahydropyranyladriamycin, a new anthracycline derivative; its effectiveness in lymphoid malignancies.

Authors:  T Takagi; M Oguro
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

2.  A phase II study of (2"R)-4'-0-tetrahydropyranyladriamycin (THP) in hematological malignancies.

Authors:  K Yamada; S Shirakawa; R Ohno; H Yamada; Y Hirota; K Ohara; K Yamagata; M Kobayashi; M Hirano; Y Ikeda
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

3.  Treatment of acute leukemia and malignant lymphoma with (2"R)-4'-O-tetrahydropyranyladriamycin.

Authors:  R Ohno; K Kimura; I Amaki; M Hirano; A Hoshino; Y Ikeda; I Kimura; M Kobayashi; K Konno; H Majima
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

4.  Intravesical administration of pirarubicin against superficial bladder cancer: Relationship between tumor tissue concentration and exposure time in the bladder or therapeutic effect.

Authors:  Maki Arakawa; Kogenta Nakamura; Yoshiaki Yamada; Kimihito Kato; Remi Katsuda; Motoi Tobiume; Kenji Zennami; Masayuki Watanabe; Yoshiharu Kato; Genya Nishikawa; Takahiko Yoshizawa; Shigeyuki Aoki; Tomohiro Taki; Kenji Mitsui; Nobuaki Honda; Hiroko Saito; Takaaki Hasegawa
Journal:  Exp Ther Med       Date:  2011-06-30       Impact factor: 2.447

5.  Phase I clinical trial and pharmacokinetic evaluation of 4'-0-tetrahydropyranyladriamycin (THP-adriamycin).

Authors:  M N Raber; R A Newman; K Lu; S Legha; C Gorski; R S Benjamin; I H Krakoff
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

6.  Single Short Retention Instillation of Pirarubicin Prevents Intravesical Recurrence of Low-risk Non Muscle Invasive Bladder Cancer.

Authors:  Susumu Kageyama; Koki Maeda; Shigehisa Kubota; Tetsuya Yoshida; Takashi Osafune; Yutaka Arai; Hiroki Soga; Zenkai Nishikawa; Yuji Sakano; Keita Takimoto; Chul Jang Kim; Tokuhiro Chano; Akihiro Kawauchi
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

7.  Prevention of peritoneal carcinomatosis from colon cancer cell seeding using a pirarubicin solution in rats and nude mice.

Authors:  Patrick Favoulet; Laurent Benoit; Liliana Osmak; Emmanuel Polycarpe; Philippe Esquis; Christian Duvillard; Boris Guiu; Patrick Rat; Jean Pierre Favre; Bruno Chauffert
Journal:  World J Surg       Date:  2004-04-19       Impact factor: 3.352

8.  Evaluation of anthracycline cardiotoxicity with the model of isolated, perfused rat heart: comparison of new analogues versus doxorubicin.

Authors:  P Pouna; S Bonoron-Adèle; G Gouverneur; L Tariosse; P Besse; J Robert
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

9.  Pharmacokinetics and disposition of 4'-O-tetrahydropyranyladriamycin in mice by HPLC analysis.

Authors:  H Iguchi; H Tone; T Ishikura; T Takeuchi; H Umezawa
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

10.  Laser flow cytometric studies on the intracellular accumulation of anthracyclines when combined with heat.

Authors:  Y Sakaguchi; Y Maehara; S Inutsuka; I Takahashi; M Yoshida; Y Emi; H Baba; K Sugimachi
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.